{"id":69586,"date":"2026-07-08T14:08:09","date_gmt":"2026-07-08T06:08:09","guid":{"rendered":"https:\/\/flcube.com\/?p=69586"},"modified":"2026-07-08T14:08:10","modified_gmt":"2026-07-08T06:08:10","slug":"nanjing-pharmaceutical-acquires-majority-stakes-in-datsing-bio-tech-and-kejian-technology-for-rmb-750-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69586","title":{"rendered":"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600713:SHA\">SHA: 600713<\/a>) announced that its holding subsidiary, <strong>Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd.<\/strong> (Qianglian No. 1 Fund), has acquired a <strong>44.95% stake in Beijing Datsing Bio-Tech Co., Ltd.<\/strong> (Datsing Bio-Tech) and a <strong>50.98% stake in Beijing Kejian Technology Co., Ltd.<\/strong> (Kejian Technology) for a total consideration of <strong>approximately RMB 750 million<\/strong> (\u2248 USD 104 million).<\/p>\n\n\n\n<h2 id=\"h-transaction-details-amp-ownership-structure\" class=\"wp-block-heading\">Transaction Details &amp; Ownership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund<\/td><\/tr><tr><td><strong>Parent Company<\/strong><\/td><td>Nanjing Pharmaceutical Co., Ltd. (SHA: 600713)<\/td><\/tr><tr><td><strong>Target Companies<\/strong><\/td><td>Beijing Datsing Bio-Tech Co., Ltd.<br>Beijing Kejian Technology Co., Ltd.<\/td><\/tr><tr><td><strong>Stake Acquired<\/strong><\/td><td>44.95% in Datsing Bio-Tech<br>50.98% in Kejian Technology<\/td><\/tr><tr><td><strong>Total Consideration<\/strong><\/td><td>RMB 750 million (~USD 104 million)<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Strategic equity investment<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>8 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-target-company-profiles-amp-strategic-rationale\" class=\"wp-block-heading\">Target Company Profiles &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beijing Datsing Bio-Tech Co., Ltd.<\/strong>: A biotechnology company focused on <strong>innovative drug development<\/strong> and <strong>biopharmaceutical manufacturing<\/strong>, with expertise in recombinant protein therapeutics and cell-based therapies. The 44.95% stake positions Nanjing Pharmaceutical as the largest single shareholder.<\/li>\n\n\n\n<li><strong>Beijing Kejian Technology Co., Ltd.<\/strong>: A technology-driven enterprise specializing in <strong>pharmaceutical equipment<\/strong>, <strong>automation systems<\/strong>, and <strong>digital solutions<\/strong> for pharmaceutical manufacturing, supporting industry modernization and compliance with international GMP standards.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The dual acquisition reflects Nanjing Pharmaceutical&#8217;s <strong>vertical integration strategy<\/strong>, combining upstream biotechnology capabilities with downstream manufacturing technology to strengthen its position across the pharmaceutical value chain.<\/p>\n\n\n\n<h2 id=\"h-financial-implications-amp-investment-strategy\" class=\"wp-block-heading\">Financial Implications &amp; Investment Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Capital Allocation<\/strong>: The RMB 750 million investment represents a significant strategic allocation by Nanjing Pharmaceutical, demonstrating confidence in China&#8217;s biopharmaceutical innovation ecosystem and manufacturing modernization trends.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Control Position<\/strong>: With <strong>50.98% ownership of Kejian Technology<\/strong>, Nanjing Pharmaceutical gains majority control, enabling direct influence over strategic direction and operational decisions. The <strong>44.95% stake in Datsing Bio-Tech<\/strong> provides substantial influence while potentially preserving the target&#8217;s entrepreneurial culture.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Synergy Opportunities<\/strong>: The transaction creates multiple synergy pathways:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Collaboration<\/strong>: Access to Datsing&#8217;s innovative pipeline and development expertise<\/li>\n\n\n\n<li><strong>Manufacturing Integration<\/strong>: Implementation of Kejian&#8217;s advanced equipment and automation solutions across Nanjing Pharmaceutical&#8217;s production facilities<\/li>\n\n\n\n<li><strong>Technology Transfer<\/strong>: Cross-pollination of digital and biomanufacturing capabilities between portfolio companies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-industry-trends\" class=\"wp-block-heading\">Market Context &amp; Industry Trends<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biopharma Consolidation<\/strong>: The deal occurs amid accelerating consolidation in China&#8217;s pharmaceutical sector, as established players seek to acquire innovative capabilities and technological expertise.<\/li>\n\n\n\n<li><strong>Government Support<\/strong>: Both acquisitions align with China&#8217;s national strategies to enhance domestic biopharmaceutical innovation and reduce reliance on imported technologies and therapeutics.<\/li>\n\n\n\n<li><strong>Investment Vehicle Strategy<\/strong>: The use of a dedicated <strong>equity investment fund<\/strong> (Qianglian No. 1 Fund) provides Nanjing Pharmaceutical with flexible capital deployment mechanisms for future strategic acquisitions.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains information regarding strategic investments and business combinations. Actual integration outcomes may differ due to regulatory approvals, market conditions, operational challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600713_20260708_4DDI.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600713_20260708_4DDI.\"><\/object><a id=\"wp-block-file--media-237bd6d2-b1f7-4ae8-a29f-4441199a39f5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600713_20260708_4DDI.pdf\">600713_20260708_4DDI<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600713_20260708_4DDI.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-237bd6d2-b1f7-4ae8-a29f-4441199a39f5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[3334,3335],"class_list":["post-69586","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-nanjing-pharmaceutical","tag-sha-600713"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (\u2248 USD 104 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69586\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million\" \/>\n<meta property=\"og:description\" content=\"Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (\u2248 USD 104 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69586\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T06:08:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T06:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69586#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69586\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million\",\"datePublished\":\"2026-07-08T06:08:09+00:00\",\"dateModified\":\"2026-07-08T06:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69586\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Nanjing Pharmaceutical\",\"SHA: 600713\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69586#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69586\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69586\",\"name\":\"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-08T06:08:09+00:00\",\"dateModified\":\"2026-07-08T06:08:10+00:00\",\"description\":\"Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (\u2248 USD 104 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69586#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69586\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69586#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (\u2248 USD 104 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69586","og_locale":"en_US","og_type":"article","og_title":"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million","og_description":"Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (\u2248 USD 104 million).","og_url":"https:\/\/flcube.com\/?p=69586","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T06:08:09+00:00","article_modified_time":"2026-07-08T06:08:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69586#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69586"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million","datePublished":"2026-07-08T06:08:09+00:00","dateModified":"2026-07-08T06:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69586"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Nanjing Pharmaceutical","SHA: 600713"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69586#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69586","url":"https:\/\/flcube.com\/?p=69586","name":"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-08T06:08:09+00:00","dateModified":"2026-07-08T06:08:10+00:00","description":"Nanjing Pharmaceutical Co., Ltd. (SHA: 600713) announced that its holding subsidiary, Nanjing Pharmaceutical Group Qianglian No. 1 Equity Investment Fund Co., Ltd. (Qianglian No. 1 Fund), has acquired a 44.95% stake in Beijing Datsing Bio-Tech Co., Ltd. (Datsing Bio-Tech) and a 50.98% stake in Beijing Kejian Technology Co., Ltd. (Kejian Technology) for a total consideration of approximately RMB 750 million (\u2248 USD 104 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69586#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69586"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69586#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69586"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69586\/revisions"}],"predecessor-version":[{"id":69589,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69586\/revisions\/69589"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}